The clinical efficacy and safety of Decitabine combined with half of CAG regimen in older patients with acute myeloid leukemia
10.3760/cma.j.issn.0254-9026.2017.07.015
- VernacularTitle:地西他滨联合半程预激方案诱导缓解治疗老年急性髓系白血病患者的疗效与安全性
- Author:
Junfeng ZHU
;
Feng GUO
;
Jiajia LI
;
Feng ZHANG
- Keywords:
Decitabine;
Acute myeloid leukemia
- From:
Chinese Journal of Geriatrics
2017;36(7):777-779
- CountryChina
- Language:Chinese
-
Abstract:
Objectives To observe the clinical efficacy and safety of Decitabine combined with half of CAG regimen in older patients with acute myeloid leukemia.Methods 29 older patients with acute myeloid leukemia treated from June 2010 to December 2016 were randomly divided into observation group and control group.Observation group(n=14)were treated with decitabine combined with half of CAG(aclacinomycin,cytarabine,granulocyte colony-stimulating factor)regimen.The control group(n=15)were treated with CAG regimen.Results The overall effective rate was higher in observation group(78.6%)than in control group(53.5%),but there was no statistically significant difference(χ2=2.042,P=0.153).The rate of lung infections was significantly lower in observation group(28.6%)than in control group(73.3%),(χ2=5.811,P=0.016).The survival time of patients was significantly longer in observation group(17.5±5.7 months)than in control group(12.6±6.2 months),the difference was statistically significant(t=2.211,P=0.018).Conclusions The treatment program of Decitabine combined with half of CAG regimen in older patients with acute myeloid leukemiais is safe and effective,which is worthy of clinical promotion.
